<DOC>
	<DOCNO>NCT01780506</DOCNO>
	<brief_summary>This study evaluate efficacy elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( Genvoya® ; E/C/F/TAF ) fixed-dose combination ( FDC ) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( Stribild® ; E/C/F/TDF ) FDC HIV-1 positive , antiretroviral treatment-naive adult .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy E/C/F/TAF ( Genvoya® ) Versus E/C/F/TDF ( Stribild® ) HIV-1 Positive , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key Ability understand sign write informed consent form , must obtain prior initiation study procedure Plasma HIV1 RNA level ≥ 1,000 copies/mL screen No prior use approve investigational antiretroviral drug length time , except use preexposure prophylaxis ( PREP ) postexposure prophylaxis ( PEP ) , 6 month prior screen Screening genotype report must show sensitivity elvitegravir , emtricitabine , tenofovir disoproxil fumarate ( tenofovir DF ) Normal electrocardiogram ( ECG ) Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min accord CockcroftGault formula creatinine clearance Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 × ULN Males females childbearing potential must agree utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 30 day follow last dose study drug Females utilize hormonal contraceptive one birth control method must use method least three month prior study dose Females stop menstruate ≥ 12 month documentation ovarian hormonal failure must serum follicle stimulate hormone ( FSH ) level screen within postmenopausal range base Central Laboratory reference range Key A new acquire immunodeficiency syndrome ( AIDS ) define condition diagnose within 30 day prior screen Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C antibody positive Individuals experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance use judge Investigator potentially interfere study compliance History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Any clinical condition prior therapy , opinion Investigator , would make individual unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval Individuals receive ongoing therapy drug use elvitegravir , cobicistat , emtricitabine , tenofovir DF , TAF individual know allergy excipients E/C/F/TDF E/C/F/TAF singletablet regimen tablet Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV 1 Infected</keyword>
	<keyword>Female</keyword>
	<keyword>Women</keyword>
</DOC>